Tobrex tobramycin ophthalmic ointment 0.3%

Manufacturer
Rebel Distributors Corp
Effective date
2010-12-01
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 20:10:43

Label at a glance#

ProductTobrex
Active ingredienttobramycin
Label structure11 sections

Indications and uses

TOBREX (tobramycin ophthalmic ointment) 0.3 % is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of TOBREX (tobramycin ophthalmic ointment) 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.

Dosage and administration

In mild to moderate disease, apply a half-inch ribbon into the affected eye(s) two or three times per day. In severe infections, instill a half-inch ribbon into the affected eye(s) every three to four hours until improvement, following which treatment should be reduced prior to discontinuation. How to Apply TOBREX (tobramycin ophthalmic ointment) 0.3%: 1. Tilt your head back. 2. Place a finger on your cheek just u...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

TOBREX® (tobramycin ophthalmic ointment) 0.3% is a sterile topical ophthalmic antibiotic formulation prepared specifically for topical therapy of external ophthalmic infections.

Each gram of TOBREX (tobramycin ophthalmic ointment) 0.3% contains: Active: tobramycin 0.3% (3 mg). Preservative: chlorobutanol 0.5%. Inactives: mineral oil, white petrolatum.

Tobramycin is a water-soluble aminoglycoside antibiotic active against a wide variety of gram-negative and gram-positive ophthalmic pathogens.

The chemical structure of tobramycin is :

Chemical StructureChemical Structure

Molecular formula:

C18H37N5O9

Molecular weight:

467.52

Chemical name:

0-{3-amino-3-deoxy-α-D-gluco-pyranosyl-(1→4) }-0-{2,6-diamino-2,3,6-trideoxy-α-D-ribohexo-pyranosyl-(1→6) }-2-deoxystreptamine.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

In Vitro Data: In vitro studies have demonstrated tobramycin is active against susceptible strains of the following microorganisms: Staphylococci, including S. aureus and S. epidermidis (coagulase- positive and coagulase-negative), including penicillin-resistant strains.

Streptococci, including some of the Group A–beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae.

Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. Bacterial susceptibility studies demonstrate that in some cases, microorganisms resistant to gentamicin retain susceptibility to tobramycin.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

TOBREX (tobramycin ophthalmic ointment) 0.3 % is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of TOBREX (tobramycin ophthalmic ointment) 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

TOBREX (tobramycin ophthalmic ointment) 0.3% is contraindicated in patients with known hypersensitivity to any of its components.

WARNINGS

WARNINGS SECTION

NOT FOR INJECTION INTO THE EYE. Sensitivity to topically applied aminoglycosides may occur in some patients. If a sensitivity reaction to TOBREX (tobramycin ophthalmic ointment) 0.3 % occurs, discontinue use.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, appropriate therapy should be initiated. Ophthalmic ointments may retard corneal wound healing.

Cross-sensitivity to other aminoglycoside antibiotics may occur; if hypersensitivity develops with this product, discontinue use and institute appropriate therapy.

Patients should be advised not to wear contact lenses if they have signs and symptoms of ocular infections.

Information For Patients

INFORMATION FOR PATIENTS SECTION

Do not touch tube tip to any surface, as this may contaminate the ointment.

Do not use the product if the imprinted carton seals have been damaged, or removed.

Pregnancy Category B

SPL UNCLASSIFIED SECTION

Reproduction studies in three types of animals at doses up to thirty-three times the normal human systemic dose have revealed no evidence of impaired fertility or harm to the fetus due to tobramycin. There are, however, no adequate and well-controlled studies in pregnant women. Because animal studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

Because of the potential for adverse reactions in nursing infants from TOBREX® (tobramycin ophthalmic ointment) 0.3 %, a decision should be made whether to discontinue nursing the infant or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in pediatric patients below the age of 2 months has not been established.

Geriatric Use

GERIATRIC USE SECTION

No overall clinical differences in safety or effectiveness have been observed between the elderly and other adult patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The most frequent adverse reactions to TOBREX (tobramycin ophthalmic ointment) 0.3% are hypersensitivity and localized ocular toxicity, including lid itching and swelling, and conjunctival erythema. These reactions occur in less than three of 100 patients treated with TOBREX (tobramycin ophthalmic ointment) 0.3%. Similar reactions may occur with the topical use of other aminoglycoside antibiotics. Other adverse reactions have not been reported from TOBREX (tobramycin ophthalmic ointment) 0.3% therapy; however, if topical ocular tobramycin is administered concomitantly with systemic aminoglycoside antibiotics, care should be taken to monitor the total serum concentration. In clinical trials, TOBREX (tobramycin ophthalmic ointment) 0.3% produced significantly fewer adverse reactions (3.7%) than did GARAMYCIN® Ophthalmic Ointment (10.6%).

OVERDOSAGE

OVERDOSAGE SECTION

Clinically apparent signs and symptoms of an overdose of TOBREX (tobramycin ophthalmic ointment) 0.3% (punctate keratitis, erythema, increased lacrimation, edema and lid itching) may be similar to adverse reaction effects seen in some patients.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

In mild to moderate disease, apply a half-inch ribbon into the affected eye(s) two or three times per day. In severe infections, instill a half-inch ribbon into the affected eye(s) every three to four hours until improvement, following which treatment should be reduced prior to discontinuation.

How to Apply TOBREX (tobramycin ophthalmic ointment) 0.3%:

1. Tilt your head back.

2. Place a finger on your cheek just under your eye and gently pull down until a ‘‘V’’ pocket is formed between your eyeball and your lower lid.

3. Place a small amount (about 1/2 inch) of TOBREX (tobramycin ophthalmic ointment) 0.3 % in the ‘‘V’’ pocket. Do not let the tip of the tube touch your eye.

4. Look downward before closing your eye.

HOW SUPPLIED

HOW SUPPLIED SECTION

3.5g STERILE ointment supplied in an aluminum tube with a white polyethylene tip and white polyethylene cap (NDC 0065-0644-35), containing tobramycin 0.3% (3 mg/g).

Storage: Store at 8° - 27°C (46°- 80°F).

Rx Only

Alcon LogoAlcon Logo

Manufactured for:

ALCON LABORATORIES, INC.

Fort Worth, Texas  76134  USA

Manufactured by:

S.A. ALCON-COUVREUR N.V.

Puurs, Belgium

Repackaged by:

REBEL DISTRIBUTORS CORP

Thousand Oaks, CA 91320

Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Trobrex 0.3%Trobrex 0.3%

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
313414tobramycin 0.3 % Ophthalmic OintmentPSN1
207850Tobrex 0.3 % Ophthalmic OintmentPSN1
207850tobramycin 0.003 MG/MG Ophthalmic Ointment [Tobrex]SBD1
313414tobramycin 0.003 MG/MG Ophthalmic OintmentSCD1
313414tobramycin 0.3 % Ophthalmic OintmentSY1
207850Tobrex 0.003 MG/MG Ophthalmic OintmentSY1
207850Tobrex 0.3 % Ophthalmic OintmentSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
TOBRAMYCIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
f297c7c1-845a-4369-8c02-c51b92d6ae8eProduct name320240725
551d952d-4ce2-24f0-9ab0-630ad9aae596Product name220231211
941f67d9-7f03-56d2-750c-36de24f654dbProduct name320221117
9cfa145f-dbe9-bc02-83c2-692786ef6676Product name920210928
2f9713b8-5e7e-bbcc-b364-1b2c27a63796Product name420210903
32a533bc-01c7-2b9f-bbf7-ecfb0d964277Product name420210625
9f5124fb-08b0-4c3e-8e12-a1a6ff310cbaProduct name120150309
745a62af-e1c0-4ca3-6d6e-2b6455b903beProduct name120140508
9ea85abb-fa68-5da6-ab60-2c7eef579000Product name120140508
aa1cd319-ece7-51f7-3a9d-52a64f5f4e81Product name120140508
d029211e-5e6b-725f-3696-ac6ff77da222Product name120140508
ef5b7aed-2b01-3ba8-5a1c-3bc9c9f03bb1Product name120140508

FDA-Initiated Inactive NDC Indexing#

NDC, Effective, Action table
NDCEffectiveActionDocumentIndexing SPLRelated label
21695-458-352019-09-24C16284748780-1934fe258-4a76-48b1-e053-8cdaa90a720aTobrex tobramycin ophthalmic ointment 0.3%

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
21695-458-35Tobrex3.5 g in 1 TUBEOINTMENT3.51

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
21695-458TOBREX (TOBRAMYCIN) OINTMENT [REBEL DISTRIBUTORS CORP]1Legacy NDC, 1 package rows20101210_3d4be22b-7a8c-4247-ac35-143611342de1.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
21695-458-35GM - Gram21695-458018facd8-9178-41b4-98ff-8ca67e07f6de12012-07-24
0065-0644-35GM - Gram0065-064424ae6212-ff8a-4b89-a629-0995489e351c12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
tobramycinACTIVE INGREDIENTVZ8RRZ51VK1
tobramycinACTIVE MOIETYVZ8RRZ51VK1
chlorobutanolINACTIVE INGREDIENTHM4YQM8WRC1
MINERAL OILINACTIVE INGREDIENTT5L8T28FGP1
PETROLATUMINACTIVE INGREDIENT4T6H12BN9U1

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 5 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
21695-45821695-458-35
0065-0644

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 4 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 2 · 64 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
PETROLATUMPETROLATUM4T6H12BN9UOINTMENT, AUGMENTED / TOPICAL81.94 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPOINTMENT / TOPICAL9938 mgExact identifier — unii candidate
30 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UTABLET, EXTENDED RELEASE / ORAL0.18 mgExact identifier — unii candidate
18 equally ranked IID candidates
chlorobutanolCHLOROBUTANOLHM4YQM8WRCINHALANT / RESPIRATORY (INHALATION)3 mgExact identifier — unii candidate
16 equally ranked IID candidates
chlorobutanolCHLOROBUTANOLHM4YQM8WRCSOLUTION / OPHTHALMIC1.1 %w/vExact identifier — unii candidate
16 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UCREAM / TOPICAL4213 mgExact identifier — unii candidate
18 equally ranked IID candidates
chlorobutanolCHLOROBUTANOLHM4YQM8WRCINJECTION / SUBCUTANEOUS60 mgExact identifier — unii candidate
16 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPTABLET, COATED / ORAL1.5 mgExact identifier — unii candidate
30 equally ranked IID candidates
chlorobutanolCHLOROBUTANOLHM4YQM8WRCINJECTION / INTRAVENOUS60 mgExact identifier — unii candidate
16 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSPRAY / TOPICAL1379 mgExact identifier — unii candidate
30 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UCAPSULE, EXTENDED RELEASE / ORAL0.07 mgExact identifier — unii candidate
18 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9USPONGE / TOPICALNAExact identifier — unii candidate
18 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UOINTMENT / OPHTHALMIC88.4 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
chlorobutanolCHLOROBUTANOLHM4YQM8WRCDROPS / NASAL500 mgExact identifier — unii candidate
16 equally ranked IID candidates
chlorobutanolCHLOROBUTANOLHM4YQM8WRCINJECTION / PARENTERAL0.5 %w/vExact identifier — unii candidate
16 equally ranked IID candidates
chlorobutanolCHLOROBUTANOLHM4YQM8WRCSOLUTION / RESPIRATORY (INHALATION)0.5 %w/wExact identifier — unii candidate
16 equally ranked IID candidates
chlorobutanolCHLOROBUTANOLHM4YQM8WRCDROPS / OPHTHALMIC0.5 %w/wExact identifier — unii candidate
16 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPOINTMENT / AURICULAR (OTIC)NAExact identifier — unii candidate
30 equally ranked IID candidates
chlorobutanolCHLOROBUTANOLHM4YQM8WRCINJECTION / INTRAMUSCULAR60 mgExact identifier — unii candidate
16 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPTABLET, FILM COATED / ORALNAExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSYSTEM / TOPICAL654.36 mgExact identifier — unii candidate
30 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UOINTMENT / VAGINAL4084 mgExact identifier — unii candidate
18 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UCREAM, AUGMENTED / TOPICAL26 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSUSPENSION / AURICULAR (OTIC)0.5 %w/vExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSYSTEM / TRANSDERMAL6.09 mgExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPDROPS / ORALNAExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSUPPOSITORY / VAGINAL30 mgExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPPASTE / DENTAL95 %w/wExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPFILM / TRANSDERMAL11.42 mgExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPTABLET / ORAL113.75 mgExact identifier — unii candidate
30 equally ranked IID candidates
chlorobutanolCHLOROBUTANOLHM4YQM8WRCOINTMENT / OPHTHALMIC0.65 %w/wExact identifier — unii candidate
16 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UOINTMENT / AURICULAR (OTIC)NAExact identifier — unii candidate
18 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSUSPENSION / TOPICAL82 %w/wExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPCAPSULE / ORAL120 mgExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPTABLET, CHEWABLE / ORAL6 mgExact identifier — unii candidate
30 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9USOAP / TOPICAL0.85 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPCREAM / TOPICAL2772 mgExact identifier — unii candidate
30 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UOINTMENT / TOPICAL7275 mgExact identifier — unii candidate
18 equally ranked IID candidates
chlorobutanolCHLOROBUTANOLHM4YQM8WRCSPRAY, METERED / NASAL20 mgExact identifier — unii candidate
16 equally ranked IID candidates
chlorobutanolCHLOROBUTANOLHM4YQM8WRCLIQUID / TOPICAL0.5 %w/wExact identifier — unii candidate
16 equally ranked IID candidates
chlorobutanolCHLOROBUTANOLHM4YQM8WRCSOLUTION / NASAL5.25 mg/1mlExact identifier — unii candidate
16 equally ranked IID candidates
chlorobutanolCHLOROBUTANOLHM4YQM8WRCSUSPENSION / INTRAMUSCULAR3.5 mgExact identifier — unii candidate
16 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPCREAM / VAGINAL402 mgExact identifier — unii candidate
30 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UTABLET / ORAL3.5 mgExact identifier — unii candidate
18 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSUPPOSITORY / RECTALNAExact identifier — unii candidate
30 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9ULOTION / TOPICAL25 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
chlorobutanolCHLOROBUTANOLHM4YQM8WRCTABLET / ORALNAExact identifier — unii candidate
16 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPOIL / TOPICAL43.29 %v/vExact identifier — unii candidate
30 equally ranked IID candidates
chlorobutanolCHLOROBUTANOLHM4YQM8WRCLIQUID / RESPIRATORY (INHALATION)0.5 %w/wExact identifier — unii candidate
16 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPTABLET, EXTENDED RELEASE / ORALNAExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPTABLET, DELAYED RELEASE / ORAL5.67 mgExact identifier — unii candidate
30 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9USUPPOSITORY / VAGINAL27 mgExact identifier — unii candidate
18 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPSOAP / TOPICAL0.82 %w/wExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPFILM, EXTENDED RELEASE / TRANSDERMAL34 mgExact identifier — unii candidate
30 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9ULIQUID / RESPIRATORY (INHALATION)NAExact identifier — unii candidate
18 equally ranked IID candidates
PETROLATUMPETROLATUM4T6H12BN9UEMULSION / TOPICAL7.8 %w/wExact identifier — unii candidate
18 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPGEL / TOPICAL2.5 %w/wExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPCAPSULE, EXTENDED RELEASE / ORAL120 mgExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPOINTMENT / OPHTHALMIC59.5 %w/wExact identifier — unii candidate
30 equally ranked IID candidates
MINERAL OILMINERAL OILT5L8T28FGPPASTE / TOPICAL47.5 %w/wExact identifier — unii candidate
30 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N050555-001TOBREXTOBRAMYCIN0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 1982

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 198284e616aacf4f…
2026-08-18 06:07:402026-07N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 19825bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 1982d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 1982d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 198279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 1982301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 19821e350fbaab3a…
2024-05-31 18:47 UTC2024-05N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 19828072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 19825c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 19825d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 19824b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 198274a2ff9319b5…
2022-03-09 01:35 UTC2022-03N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 1982bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 1982782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 198287673890dc5c…
2021-03-12 10:30 UTC2021-03N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 19825aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 19828869cabd3fbd…
2020-11-12 02:37 UTC2020-11N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 1982c0c555d07b60…
2019-12-14 00:12 UTC2019-12N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 19823f01610625f2…
2019-09-15 20:21 UTC2019-09N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 1982b00525d2431f…
2019-07-19 19:46 UTC2019-07N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 1982ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 19826a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 19821c564ffb4f44…
2023-12-20 04:57 UTC2023-12N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 1982ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 1982a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 19829b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 1982a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 19823f0d92c62455…
2023-05-13 08:27 UTC2023-05N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 1982053a50430f4f…
2023-01-26 05:58 UTC2023-01N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 19823bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 19823a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N050555-001TOBREX0.3%OINTMENT / OPHTHALMICRLD, RS, Approved before 1982f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
3d4be22b-7a8c-4247-ac35-143611342de13d4be22b-7a8c-4247-ac35-143611342de12010-12-01Warnings, Adverse reactionsExact identifier
spl id: 3d4be22b-7a8c-4247-ac35-143611342de1
spl set id: 3d4be22b-7a8c-4247-ac35-143611342de1

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.